Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy
Watanabe S, Okamoto S, Akikawa K, Miyamoto N, Okamura-Kawasaki M, Uchiyama Y, Takenaka J, Toyonaga T, Hirata K, Kudo K. Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy. Annals Of Nuclear Medicine 2022, 36: 923-930. PMID: 35972673, DOI: 10.1007/s12149-022-01781-1.Peer-Reviewed Original ResearchConceptsProbability of remissionHigh-dose RAIRemission rateThyroid-stimulating antibodiesGraves' diseaseIodine therapyDose groupHD groupThyroid volumeHigh-dose radioactive iodine (RAI) therapyThyroid hormone replacement therapyMultivariate logistic regression analysisLD groupHigher RAI doseRadioactive iodine therapyCharacteristics of patientsOverall remission rateHormone replacement therapyLow-dose groupHigh-dose groupIdentification of patientsLogistic regression analysisMultivariate analysis resultsDose RAIRAI dose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply